<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00630</drugbank-id>
  <drugbank-id>APRD00561</drugbank-id>
  <name>Alendronic acid</name>
  <description>Alendronic acid is a bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959]. It functions by preventing resorption of bone[FDA Label][A959].</description>
  <cas-number>66376-36-1</cas-number>
  <unii>X1J18R4W8P</unii>
  <average-mass>249.096</average-mass>
  <monoisotopic-mass>249.016724799</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A959</ref-id>
        <pubmed-id>18214569</pubmed-id>
        <citation>Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8.</citation>
      </article>
      <article>
        <ref-id>A176750</ref-id>
        <pubmed-id>10384857</pubmed-id>
        <citation>Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999 May;36(5):315-28. doi: 10.2165/00003088-199936050-00002.</citation>
      </article>
      <article>
        <ref-id>A176768</ref-id>
        <pubmed-id>1356743</pubmed-id>
        <citation>Lin JH, Chen IW, Deluna FA, Hichens M: Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos. 1992 Jul-Aug;20(4):608-13.</citation>
      </article>
      <article>
        <ref-id>A176771</ref-id>
        <pubmed-id>8246140</pubmed-id>
        <citation>Lin JH, Chen IW, deLuna FA, Hichens M: Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther. 1993 Nov;267(2):670-5.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Masahiko Dohi, Yuji Makino, Takao Hujii, "Sodium alendronate preparation for local administration." U.S. Patent US5958908, issued September, 1997.</synthesis-reference>
  <indication>Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance &lt;35mL/min[FDA Label].</indication>
  <pharmacodynamics>Alendronic acid tablets have a very low oral bioavialability[FDA Label][A176750]. After administration it distributes into soft tissue and bone or is excreted in the urine[FDA Label]. Alendronic acid does not undergo metabolism[FDA Label].</pharmacodynamics>
  <mechanism-of-action>Alendronic acid binds to bone hydroxyapatite[FDA Label]. Bone resorption causes local acidification, releasing alendronic acid which is that taken into osteoclasts by fluid-phase endocytosis[A959]. Endocytic vesicles are acidified, releasing alendronic acid to the cytosol of osteoclasts where they induce apoptosis[A959]. Inhibition of osteoclasts results in decreased bone resorption which is shown through decreased urinary calcium, deoxypyridinoline and cross-linked N-telopeptidases of type I collagen[FDA Label].</mechanism-of-action>
  <toxicity>In clinical studies, â‰¥3% of patients experience abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, and nausea[FDA Label].&#13;
&#13;
No information for treatment of overdose is available, however patients should be given milk or antacids to bind alendronic acid and vomiting should not be induced[FDA Label]. Patients may experience hypocalcemia, hypophosphatemia, and upper gastrointestinal events.[FDA Label].&#13;
&#13;
There are currently no studies for safety and efficacy in pregnancy, though studies in pregnant rats show fetal and maternal complications at 4 times the clinical dose and pregnant rabbits do not show complications at as high as 10 times the clincal dose[FDA Label].&#13;
&#13;
Excretion in breast milk, and therefore safety in lactation, is unknown[FDA Label].&#13;
&#13;
Alendronic acid has been studied for use in pediatric patients[FDA Label]. The oral bioavailability is similar to that in adult patients, but an increase in the portion of patients experiencing vomiting[FDA Label].&#13;
&#13;
There is no significant difference in efficacy or safety of alendronic acid in geriatric populations, though there is potential for even greater sensitivity in patients at a further advanced age than those in the study[FDA Label].&#13;
&#13;
Alendronic acid is not recommended for patients with creatinine clearance &lt;35mL/min, but no dosage adjustment is necessary in hepatic impairment[FDA Label].</toxicity>
  <metabolism>Urinary excretion is the sole method of elimination of alendronic acid and no metabolites are detected upon urine collection[A176750].</metabolism>
  <absorption>Mean oral bioavailability of alendronic acid in women is 0.64% and in men is 0.59%[FDA Label][A176750]. Bioavailability of alendronic acid decreases by up to 40% if it is taken within an hour of a meal[FDA Label].</absorption>
  <half-life>Due to alendronic acid being incorporated into the skeleton, the terminal half life is estimated to be over 10 years[FDA Label].</half-life>
  <protein-binding>78%[FDA Label]. Studies in rats show that plasma protein binding increases with decreasing alendronic acid plasma concentration[A176768] and increasing pH[A176771].</protein-binding>
  <route-of-elimination>Administration of radiolabeled alendronic acid results in 50% recovery in urine within 72 hours[FDA Label][A176771]. No alendronic acid is recovered in the feces[FDA Label][A176750,A176768]. Men excrete less alendronic acid than women, though race and advanced age do not affect elimination[FDA Label].</route-of-elimination>
  <volume-of-distribution>28L[FDA Label].</volume-of-distribution>
  <clearance>71mL/min[FDA Label].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.</description>
    <direct-parent>Bisphosphonates</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Organic phosphonic acids and derivatives</class>
    <subclass>Bisphosphonates</subclass>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic phosphonic acids</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organophosphorus compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Amine</substituent>
    <substituent>Bisphosphonate</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organophosphonic acid</substituent>
    <substituent>Organophosphorus compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001780</drugbank-id>
      <name>Alendronate calcium</name>
      <unii>3JTA994BVH</unii>
      <cas-number>137504-90-6</cas-number>
      <inchikey>VFAZUESUCBECNE-UHFFFAOYSA-L</inchikey>
      <average-mass>536.253</average-mass>
      <monoisotopic-mass>535.9803924</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000315</drugbank-id>
      <name>Alendronate sodium</name>
      <unii>2UY4M2U3RA</unii>
      <cas-number>121268-17-5</cas-number>
      <inchikey>DCSBSVSZJRSITC-UHFFFAOYSA-M</inchikey>
      <average-mass>325.1237</average-mass>
      <monoisotopic-mass>325.0303635</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001779</drugbank-id>
      <name>Alendronate sodium anhydrous</name>
      <unii>4988K7X26P</unii>
      <cas-number>129318-43-0</cas-number>
      <inchikey>CAKRAHQRJGUPIG-UHFFFAOYSA-M</inchikey>
      <average-mass>271.077</average-mass>
      <monoisotopic-mass>270.99867001</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="iupac">(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)</synonym>
    <synonym language="english" coder="">(4-amino-1-hydroxybutylidene)bisphosphonic acid</synonym>
    <synonym language="english" coder="">4-amino-1-hydroxybutane-1,1-diphosphonic acid</synonym>
    <synonym language="english" coder="">ABDP</synonym>
    <synonym language="french" coder="inn">Acide Alendronique</synonym>
    <synonym language="spanish" coder="inn">Acido Alendronico</synonym>
    <synonym language="latin" coder="inn">Acidum Alendronicum</synonym>
    <synonym language="english" coder="">Alendronate</synonym>
    <synonym language="english" coder="inn">Alendronic acid</synonym>
  </synonyms>
  <products>
    <product>
      <name>Accel-alendronate</name>
      <labeller>Accel Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401118</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Accel-alendronate</name>
      <labeller>Accel Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401126</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-26</started-marketing-on>
      <ended-marketing-on>2017-09-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Accel-alendronate</name>
      <labeller>Accel Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401134</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-26</started-marketing-on>
      <ended-marketing-on>2017-09-13</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ach-alendronate</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02381486</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ach-alendronate</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02381494</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ach-alendronate</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02381478</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Alendronate</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258102</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-14</started-marketing-on>
      <ended-marketing-on>2019-07-08</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Act Alendronate</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02258110</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-14</started-marketing-on>
      <ended-marketing-on>2018-06-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Adrovance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000759</ema-product-code>
      <ema-ma-number>EU/1/06/364/001</ema-ma-number>
      <started-marketing-on>2007-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Adrovance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000759</ema-product-code>
      <ema-ma-number>EU/1/06/364/002</ema-ma-number>
      <started-marketing-on>2007-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Adrovance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000759</ema-product-code>
      <ema-ma-number>EU/1/06/364/003</ema-ma-number>
      <started-marketing-on>2007-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Adrovance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000759</ema-product-code>
      <ema-ma-number>EU/1/06/364/004</ema-ma-number>
      <started-marketing-on>2007-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Adrovance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000759</ema-product-code>
      <ema-ma-number>EU/1/06/364/006</ema-ma-number>
      <started-marketing-on>2007-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Adrovance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000759</ema-product-code>
      <ema-ma-number>EU/1/06/364/007</ema-ma-number>
      <started-marketing-on>2007-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Adrovance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000759</ema-product-code>
      <ema-ma-number>EU/1/06/364/008</ema-ma-number>
      <started-marketing-on>2007-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Ag-alendronate</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485168</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-alendronate</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485176</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ag-alendronate</name>
      <labeller>Angita Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485184</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2587</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3593</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>60723-207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>60723-205</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Sorres Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302004</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on>2014-06-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Sanis Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352966</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343916</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Cobalt Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02343924</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate</name>
      <labeller>Sivem Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02299712</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68258-3014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-188</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-11</started-marketing-on>
      <ended-marketing-on>2012-03-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-189</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-11</started-marketing-on>
      <ended-marketing-on>2012-03-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-11</started-marketing-on>
      <ended-marketing-on>2012-03-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-11</started-marketing-on>
      <ended-marketing-on>2012-03-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5862</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5861</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Med Pharma Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>51138-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-11</started-marketing-on>
      <ended-marketing-on>2012-03-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-993</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0719</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2010-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076184</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Barr Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0555-0720</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on>2011-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076184</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Med Vantx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66116-428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>33261-820</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-5140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-08</started-marketing-on>
      <ended-marketing-on>2018-05-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-01</started-marketing-on>
      <ended-marketing-on>2015-10-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-241</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-01</started-marketing-on>
      <ended-marketing-on>2015-10-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-04</started-marketing-on>
      <ended-marketing-on>2014-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-941</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-942</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Blu Pharmceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code>24658-162</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-05</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Blu Pharmceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code>24658-163</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-05</started-marketing-on>
      <ended-marketing-on>2015-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Department Of State Health Services, Pharmacy Branch</labeller>
      <ndc-id/>
      <ndc-product-code>55695-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1096</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-6047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-6050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-732</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-07</started-marketing-on>
      <ended-marketing-on>2014-10-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-5861</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2018-07-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>70786-0224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2018-10-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-382</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-13</started-marketing-on>
      <ended-marketing-on>2013-10-02</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3169</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3172</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-3173</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>41616-635</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-10</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>41616-636</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-10</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>41616-637</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-10</started-marketing-on>
      <ended-marketing-on>2016-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>41616-638</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-10</started-marketing-on>
      <ended-marketing-on>2016-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2592</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2593</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2594</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2596</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2015-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-15</started-marketing-on>
      <ended-marketing-on>2016-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>76439-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-15</started-marketing-on>
      <ended-marketing-on>2016-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-02</started-marketing-on>
      <ended-marketing-on>2017-03-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Aidarex Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>53217-321</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-743</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-13</started-marketing-on>
      <ended-marketing-on>2017-02-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-5860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2016-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>70786-5172</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-4120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5141</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on>2018-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5172</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5142</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on>2018-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-5171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on>2018-05-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9463</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global FZE</labeller>
      <ndc-id/>
      <ndc-product-code>47335-635</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global FZE</labeller>
      <ndc-id/>
      <ndc-product-code>47335-636</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global FZE</labeller>
      <ndc-id/>
      <ndc-product-code>47335-637</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Sun Pharma Global FZE</labeller>
      <ndc-id/>
      <ndc-product-code>47335-638</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Preferreed Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7393</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-5862</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-242</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-244</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3568</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-29</started-marketing-on>
      <ended-marketing-on>2009-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3569</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-29</started-marketing-on>
      <ended-marketing-on>2009-09-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2012-02-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Jubilant Cadista Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59746-241</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2012-02-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090557</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3987</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2013-02-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3988</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2013-02-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077982</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2017-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16252-599</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-23</started-marketing-on>
      <ended-marketing-on>2019-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16252-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2019-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3566</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2019-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-3567</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on>2018-10-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076584</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-055</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-056</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090258</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Direct_Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-729</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4076</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-175</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1676</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1678</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1679</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1680</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1681</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA075710</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Direct Rx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-689</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1802</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1803</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090022</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076984</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Nucare Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-3340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-223</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-224</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>TAGI Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51224-301</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>70 mg/75mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090520</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-631</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-632</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>NorthStar Rx LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-633</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-340</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-341</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-342</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate Sodium</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076768</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alendronate-70</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02303078</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate-cholecalciferol</name>
      <labeller>Frosst A Division Of Merck Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02405717</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alendronate-cholecalciferol</name>
      <labeller>Frosst A Division Of Merck Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02405725</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-alendronate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248727</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-alendronate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248728</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-alendronate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248730</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-alendronate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248729</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-alendronate/vitamin D3</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02454467</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-alendronate/vitamin D3</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02454475</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-alendronate</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388545</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-alendronate</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02388553</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-alendronate</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365057</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-alendronate</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365065</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-alendronate</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365073</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ava-alendronate</name>
      <labeller>Avanstra Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365081</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Binosto</name>
      <labeller>Mission Pharmacal Company</labeller>
      <ndc-id/>
      <ndc-product-code>0178-0101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, effervescent</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA202344</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Binosto</name>
      <labeller>Ascend Therapeutics</labeller>
      <ndc-id/>
      <ndc-product-code>17139-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, effervescent</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA202344</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dom-alendronate</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282763</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dom-alendronate-FC</name>
      <labeller>Dominion Pharmacal</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308398</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4384</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020560</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3857</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020560</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4463</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-02-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020560</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020560</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0925</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-18</started-marketing-on>
      <ended-marketing-on>2007-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0936</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-18</started-marketing-on>
      <ended-marketing-on>2007-05-18</ended-marketing-on>
      <dosage-form>Tablet, coated</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0077</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-18</started-marketing-on>
      <ended-marketing-on>2007-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>35 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-18</started-marketing-on>
      <ended-marketing-on>2007-05-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3833</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-18</started-marketing-on>
      <ended-marketing-on>2007-05-18</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>70 mg/75mL</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020560</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245329</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>70 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02201038</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>2013-07-15</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>40 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02201011</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>2011-11-10</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02233055</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-21</started-marketing-on>
      <ended-marketing-on>2010-07-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fosamax</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248625</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-30</started-marketing-on>
      <ended-marketing-on>2013-07-15</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>70 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fosamax Plus D</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5480</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021762</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax Plus D</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0710</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021762</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosamax Plus D</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-0270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021762</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000619</ema-product-code>
      <ema-ma-number>EU/1/05/310/001</ema-ma-number>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000619</ema-product-code>
      <ema-ma-number>EU/1/05/310/002</ema-ma-number>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000619</ema-product-code>
      <ema-ma-number>EU/1/05/310/003</ema-ma-number>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000619</ema-product-code>
      <ema-ma-number>EU/1/05/310/004</ema-ma-number>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000619</ema-product-code>
      <ema-ma-number>EU/1/05/310/006</ema-ma-number>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000619</ema-product-code>
      <ema-ma-number>EU/1/05/310/007</ema-ma-number>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000619</ema-product-code>
      <ema-ma-number>EU/1/05/310/008</ema-ma-number>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02276429</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fosavance</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02314940</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gen-alendronate</name>
      <labeller>Genpharm Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270110</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-25</started-marketing-on>
      <ended-marketing-on>2009-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-alendronate</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02385031</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-alendronate</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02385015</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-alendronate</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02385023</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-alendronate</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02394863</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-21</started-marketing-on>
      <ended-marketing-on>2018-08-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-alendronate</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02394871</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-11-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-alendronate</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02394855</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-alendronate</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02286335</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-29</started-marketing-on>
      <ended-marketing-on>2018-07-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mylan-alendronate</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270129</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-25</started-marketing-on>
      <ended-marketing-on>2017-09-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-alendronate</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282771</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-17</started-marketing-on>
      <ended-marketing-on>2016-10-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-alendronate</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02273179</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-11-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-alendronate-FC</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284006</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Q-alendronate</name>
      <labeller>Qd Pharmaceuticals Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372304</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-01</started-marketing-on>
      <ended-marketing-on>2015-08-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-alendronate</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02384728</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-alendronate</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02384698</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-alendronate</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02384701</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio Alendronate</name>
      <labeller>Ratiopharm Inc Division Of Teva Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02275279</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-08</started-marketing-on>
      <ended-marketing-on>2014-09-19</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva Alendronate</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270870</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-alendronate</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270889</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-alendronate</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02476398</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-alendronate</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02476401</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Alendronate</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288079</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-11</started-marketing-on>
      <ended-marketing-on>2016-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Alendronate</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288095</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Alendronate</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288087</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Alendronate</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288109</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Alendronate/cholecalciferol</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429160</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-alendronate</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247373</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-alendronate</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248251</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-alendronate</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261715</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-alendronate/cholecalciferol</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403633</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-alendronate/cholecalciferol</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403641</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-alendronate</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428725</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-22</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-alendronate</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428733</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-22</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Van-alendronate</name>
      <labeller>Vanc Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428717</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-22</started-marketing-on>
      <ended-marketing-on>2019-08-07</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Alenotop</name>
      <company>Pliva</company>
    </international-brand>
    <international-brand>
      <name>Alned</name>
      <company>Laboratorios Belmac</company>
    </international-brand>
    <international-brand>
      <name>Arendal</name>
      <company>Ivax</company>
    </international-brand>
    <international-brand>
      <name>Beenos</name>
      <company>Gedeon Richter</company>
    </international-brand>
    <international-brand>
      <name>Berlex</name>
      <company>Duncan</company>
    </international-brand>
    <international-brand>
      <name>Denfos</name>
      <company>Biofarma</company>
    </international-brand>
    <international-brand>
      <name>Densidron</name>
      <company>Mepha</company>
    </international-brand>
    <international-brand>
      <name>Dronat</name>
      <company>Farmavita</company>
    </international-brand>
    <international-brand>
      <name>Durost</name>
      <company>Perumed</company>
    </international-brand>
    <international-brand>
      <name>Fixopan</name>
      <company>Grupo Farma</company>
    </international-brand>
    <international-brand>
      <name>Forosa</name>
      <company>Kemofarmacija</company>
    </international-brand>
    <international-brand>
      <name>Fosagen</name>
      <company>Aspen Pharmacare</company>
    </international-brand>
    <international-brand>
      <name>Fosalen</name>
      <company>Teriak</company>
    </international-brand>
    <international-brand>
      <name>Fosmin</name>
      <company>Hospimedikka</company>
    </international-brand>
    <international-brand>
      <name>Fostolin</name>
      <company>Actavis</company>
    </international-brand>
    <international-brand>
      <name>Fosval</name>
      <company>Saval</company>
    </international-brand>
    <international-brand>
      <name>Huesobone</name>
      <company>Farmaceutica Latina</company>
    </international-brand>
    <international-brand>
      <name>Lendrate</name>
      <company>Actavis</company>
    </international-brand>
    <international-brand>
      <name>Oseolen</name>
      <company>Intipharma</company>
    </international-brand>
    <international-brand>
      <name>Ostemax</name>
      <company>Polpharma</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax Plus D</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Binosto</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Adrovance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Adrovance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Adrovance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Adrovance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Adrovance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Adrovance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Adrovance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax Plus D</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax Plus D</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate Sodium</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Binosto</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Teva-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Teva-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Apo-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Apo-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Apo-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Teva-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Dom-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate-70</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosavance</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Ach-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ach-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ran-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Auro-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Auro-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Mint-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Mint-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Teva-alendronate/cholecalciferol</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Teva-alendronate/cholecalciferol</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Alendronate/cholecalciferol</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fosamax</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Gen-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ratio Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Q-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Apo-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Mint-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate-cholecalciferol</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate-cholecalciferol</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Act Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Act Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>PMS-alendronate-FC</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ach-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Apo-alendronate/vitamin D3</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Apo-alendronate/vitamin D3</name>
      <ingredients>Alendronic acid + Cholecalciferol</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Riva Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>PHL-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Van-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Van-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ran-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ran-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>PMS-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Van-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Riva-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Mylan-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Accel-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Accel-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Accel-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Dom-alendronate-FC</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Riva-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Riva-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ag-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ag-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ag-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ava-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ava-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ava-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
    <mixture>
      <name>Ava-alendronate</name>
      <ingredients>Alendronic acid</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>Apotex Inc.</name>
      <url>http://www.apotex.com</url>
    </packager>
    <packager>
      <name>Arrow Pharm Malta Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Aurobindo Pharma Ltd.</name>
      <url>http://www.aurobindo.com</url>
    </packager>
    <packager>
      <name>Barr Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Cipla Ltd.</name>
      <url>http://www.cipla.com</url>
    </packager>
    <packager>
      <name>Cobalt Pharmaceuticals Inc.</name>
      <url>http://www.cobaltpharma.com</url>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Diversified Healthcare Services Inc.</name>
      <url>http://www.dhscorp.com</url>
    </packager>
    <packager>
      <name>Doctor Reddys Laboratories Ltd.</name>
      <url>http://www.drreddys.com</url>
    </packager>
    <packager>
      <name>Lake Erie Medical and Surgical Supply</name>
      <url/>
    </packager>
    <packager>
      <name>Merck &amp; Co.</name>
      <url>http://www.merck.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
    <packager>
      <name>Northstar Rx LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Nucare Pharmaceuticals Inc.</name>
      <url>http://www.nucarerx.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Sun Pharmaceutical Industries Ltd.</name>
      <url>http://www.sunpharma.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>UDL Laboratories</name>
      <url>http://www.udllabs.com</url>
    </packager>
    <packager>
      <name>Watson Pharmaceuticals</name>
      <url>http://www.watson.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Merck and co inc</manufacturer>
    <manufacturer generic="true" url="">Apotex inc</manufacturer>
    <manufacturer generic="true" url="">Aurobindo pharma ltd</manufacturer>
    <manufacturer generic="true" url="">Austarpharma llc</manufacturer>
    <manufacturer generic="true" url="">Barr laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Cadista pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Dr reddys laboratories ltd</manufacturer>
    <manufacturer generic="true" url="">Genpharm ulc</manufacturer>
    <manufacturer generic="true" url="">Mylan pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Sandoz inc</manufacturer>
    <manufacturer generic="true" url="">Sun pharma global inc</manufacturer>
    <manufacturer generic="true" url="">Teva pharmaceuticals usa</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Alendronate sodium 10 mg tablet</description>
      <cost currency="USD">2.99</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Alendronate sodium 5 mg tablet</description>
      <cost currency="USD">2.99</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fosamax 10 mg tablet</description>
      <cost currency="USD">3.4</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fosamax 5 mg tablet</description>
      <cost currency="USD">3.4</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Alendronate sodium 40 mg tablet</description>
      <cost currency="USD">6.73</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fosamax 40 mg tablet</description>
      <cost currency="USD">7.52</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Alendronate sodium 35 mg tablet</description>
      <cost currency="USD">20.49</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Alendronate sodium 70 mg tablet</description>
      <cost currency="USD">20.49</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fosamax plus d 70 mg-2800 iu</description>
      <cost currency="USD">21.85</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Fosamax 35 mg tablet</description>
      <cost currency="USD">23.36</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fosamax 70 mg tablet</description>
      <cost currency="USD">24.51</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Fosamax plus d 70 mg-5600 iu</description>
      <cost currency="USD">25.88</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Fosamax 70 mg/75ml Solution 75ml Bottle</description>
      <cost currency="USD">34.75</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Alendronate Sodium 4 35 mg tablet Package</description>
      <cost currency="USD">85.23</cost>
      <unit>package</unit>
    </price>
    <price>
      <description>Alendronate Sodium 4 70 mg tablet Package</description>
      <cost currency="USD">85.23</cost>
      <unit>package</unit>
    </price>
    <price>
      <description>Fosamax 1 Package = 4 tablet (35 mg) Package</description>
      <cost currency="USD">97.2</cost>
      <unit>package</unit>
    </price>
    <price>
      <description>Fosamax 1 Package = 4 tablet (70 mg) Package</description>
      <cost currency="USD">101.96</cost>
      <unit>package</unit>
    </price>
    <price>
      <description>Fosamax Plus D 4 70-2800 mg-Unit tablet Disp Pack</description>
      <cost currency="USD">107.66</cost>
      <unit>disp</unit>
    </price>
    <price>
      <description>Fosamax Plus D 4 70-5600 mg-Unit tablet Disp Pack</description>
      <cost currency="USD">107.66</cost>
      <unit>disp</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Agents Causing Muscle Toxicity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Bisphosphonates</category>
      <mesh-id>D004164</mesh-id>
    </category>
    <category>
      <category>Bone Density Conservation Agents</category>
      <mesh-id>D050071</mesh-id>
    </category>
    <category>
      <category>Drugs Affecting Bone Structure and Mineralization</category>
      <mesh-id/>
    </category>
    <category>
      <category>Drugs for Treatment of Bone Diseases</category>
      <mesh-id/>
    </category>
    <category>
      <category>Musculo-Skeletal System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Organophosphonates</category>
      <mesh-id>D063065</mesh-id>
    </category>
    <category>
      <category>Organophosphorus Compounds</category>
      <mesh-id>D009943</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>70 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, effervescent</form>
      <route>Oral</route>
      <strength>70 mg/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>70 mg/75mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>70 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>35 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>40 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>70 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="M05BB03">
      <level code="M05BB">Bisphosphonates, combinations</level>
      <level code="M05B">DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION</level>
      <level code="M05">DRUGS FOR TREATMENT OF BONE DISEASES</level>
      <level code="M">MUSCULO-SKELETAL SYSTEM</level>
    </atc-code>
    <atc-code code="M05BA04">
      <level code="M05BA">Bisphosphonates</level>
      <level code="M05B">DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION</level>
      <level code="M05">DRUGS FOR TREATMENT OF BONE DISEASES</level>
      <level code="M">MUSCULO-SKELETAL SYSTEM</level>
    </atc-code>
    <atc-code code="M05BB06">
      <level code="M05BB">Bisphosphonates, combinations</level>
      <level code="M05B">DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION</level>
      <level code="M05">DRUGS FOR TREATMENT OF BONE DISEASES</level>
      <level code="M">MUSCULO-SKELETAL SYSTEM</level>
    </atc-code>
    <atc-code code="M05BB05">
      <level code="M05BB">Bisphosphonates, combinations</level>
      <level code="M05B">DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION</level>
      <level code="M05">DRUGS FOR TREATMENT OF BONE DISEASES</level>
      <level code="M">MUSCULO-SKELETAL SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>92:24.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>5dz2</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00630.pdf?1554415365</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00630.pdf?1265922737</msds>
  <patents>
    <patent>
      <number>5358941</number>
      <country>United States</country>
      <approved>1994-10-25</approved>
      <expires>2012-12-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2190148</number>
      <country>Canada</country>
      <approved>2006-02-14</approved>
      <expires>2015-05-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2294595</number>
      <country>Canada</country>
      <approved>2001-08-21</approved>
      <expires>2018-07-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5994329</number>
      <country>United States</country>
      <approved>1999-11-30</approved>
      <expires>2019-01-17</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6015801</number>
      <country>United States</country>
      <approved>2000-01-18</approved>
      <expires>2019-01-17</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6225294</number>
      <country>United States</country>
      <approved>2001-05-01</approved>
      <expires>2019-01-17</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>7964212</number>
      <country>United States</country>
      <approved>2011-06-21</approved>
      <expires>2023-03-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7488496</number>
      <country>United States</country>
      <approved>2009-02-10</approved>
      <expires>2023-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Take 30-60 minutes before breakfast.</food-interaction>
    <food-interaction>Take with a full glass of water.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Alendronic acid is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of adverse effects can be increased when Icosapent is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Rofecoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of adverse effects can be increased when Carprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of adverse effects can be increased when Antrafenine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of adverse effects can be increased when Aminophenazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of adverse effects can be increased when Taxifolin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of adverse effects can be increased when Niflumic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The risk or severity of adverse effects can be increased when Licofelone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of adverse effects can be increased when Cimicoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of adverse effects can be increased when Felbinac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Isoxicam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Indoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of adverse effects can be increased when Ibuproxam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of adverse effects can be increased when Floctafenine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of adverse effects can be increased when Epirizole is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Loxoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of adverse effects can be increased when Dexibuprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of adverse effects can be increased when Firocoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of adverse effects can be increased when Clonixin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of adverse effects can be increased when Morniflumate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of adverse effects can be increased when Propacetamol is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of adverse effects can be increased when Talniflumate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of adverse effects can be increased when Robenacoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of adverse effects can be increased when Tepoxalin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of adverse effects can be increased when Flunixin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of adverse effects can be increased when Polmacoxib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of adverse effects can be increased when Indobufen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of adverse effects can be increased when Ebselen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of adverse effects can be increased when Tinoridine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Alclofenac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of adverse effects can be increased when Fentiazac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of adverse effects can be increased when Suxibuzone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of adverse effects can be increased when Bumadizone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Alminoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of adverse effects can be increased when Feprazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of adverse effects can be increased when Difenpiramide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of adverse effects can be increased when Nifenazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of adverse effects can be increased when Lonazolac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of adverse effects can be increased when Tenidap is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of adverse effects can be increased when Bendazac is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Pranoprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of adverse effects can be increased when Propyphenazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of adverse effects can be increased when Proglumetacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of adverse effects can be increased when Guacetisal is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of adverse effects can be increased when Ethenzamide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of adverse effects can be increased when Mofebutazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of adverse effects can be increased when Proquazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of adverse effects can be increased when Benorilate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of adverse effects can be increased when Pirprofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of adverse effects can be increased when SC-236 is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of adverse effects can be increased when NS-398 is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of adverse effects can be increased when Flurbiprofen axetil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01270</drugbank-id>
      <name>Ranibizumab</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02640</drugbank-id>
      <name>Fumagillin</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04866</drugbank-id>
      <name>Halofuginone</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05288</drugbank-id>
      <name>Anecortave acetate</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave acetate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06423</drugbank-id>
      <name>Endostatin</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06436</drugbank-id>
      <name>Semaxanib</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06461</drugbank-id>
      <name>Squalamine</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06647</drugbank-id>
      <name>Volociximab</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Volociximab is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08633</drugbank-id>
      <name>TNP-470</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when TNP-470 is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11366</drugbank-id>
      <name>Roquinimex</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11727</drugbank-id>
      <name>Endostar</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostar is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12056</drugbank-id>
      <name>Trebananib</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12081</drugbank-id>
      <name>Anecortave</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12671</drugbank-id>
      <name>Beloranib</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Beloranib is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14864</drugbank-id>
      <name>Brolucizumab</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexrabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11964</drugbank-id>
      <name>Ilaprazole</name>
      <description>The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Ilaprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>The risk or severity of hypocalcemia can be increased when Salmon Calcitonin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06773</drugbank-id>
      <name>Human calcitonin</name>
      <description>The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13189</drugbank-id>
      <name>Calcitonin porcine</name>
      <description>The risk or severity of hypocalcemia can be increased when Calcitonin porcine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13742</drugbank-id>
      <name>Elcatonin</name>
      <description>The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Geneticin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin C1a is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dibekacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Micronomicin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Isepamicin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bekanamycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Sodium bicarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium acetoacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Almasilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Aloglutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>Magnesium sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Magnesium chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>Magnesium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>Magnesium aspartate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>Magnesium gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>Magnesium orotate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>Magnesium can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14514</drugbank-id>
      <name>Magnesium levulinate</name>
      <description>Magnesium levulinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14515</drugbank-id>
      <name>Magnesium lactate</name>
      <description>Magnesium lactate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00326</drugbank-id>
      <name>Calcium glucoheptonate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glucoheptonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01164</drugbank-id>
      <name>Calcium chloride</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium Chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium Citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium Phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13142</drugbank-id>
      <name>Calcium glubionate anhydrous</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13231</drugbank-id>
      <name>Calcium lactate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13365</drugbank-id>
      <name>Calcium lactate gluconate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13590</drugbank-id>
      <name>Calcium pangamate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium pangamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13800</drugbank-id>
      <name>Calcium levulinate</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium levulinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>The risk or severity of hypocalcemia can be increased when Alendronic acid is combined with Technetium Tc-99m oxidronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of hypocalcemia can be increased when Torasemide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of hypocalcemia can be increased when Furosemide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The risk or severity of hypocalcemia can be increased when Piretanide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The risk or severity of hypocalcemia can be increased when Azosemide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00267</drugbank-id>
      <name>Cefmenoxime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmenoxime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00274</drugbank-id>
      <name>Cefmetazole</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00430</drugbank-id>
      <name>Cefpiramide</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpiramide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00447</drugbank-id>
      <name>Loracarbef</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00626</drugbank-id>
      <name>Bacitracin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00689</drugbank-id>
      <name>Cephaloglycin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephaloglycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pentamidine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00923</drugbank-id>
      <name>Ceforanide</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistimethate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01139</drugbank-id>
      <name>Cefapirin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01150</drugbank-id>
      <name>Cefprozil</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01328</drugbank-id>
      <name>Cefonicid</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01331</drugbank-id>
      <name>Cefoxitin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium cation is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01413</drugbank-id>
      <name>Cefepime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefacetrile is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02247</drugbank-id>
      <name>Hydrolyzed Cephalothin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrolyzed Cephalothin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03450</drugbank-id>
      <name>Cephalothin Group</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalothin Group is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04570</drugbank-id>
      <name>Latamoxef</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04918</drugbank-id>
      <name>Ceftobiprole</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftobiprole is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06590</drugbank-id>
      <name>Ceftaroline fosamil</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaloridine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09062</drugbank-id>
      <name>Cefminox</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefminox is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefroxadine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11935</drugbank-id>
      <name>Flomoxef</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Flomoxef is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12151</drugbank-id>
      <name>Brincidofovir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Brincidofovir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13266</drugbank-id>
      <name>Cefatrizine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13461</drugbank-id>
      <name>Cefcapene</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefcapene is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13470</drugbank-id>
      <name>Cefodizime</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13499</drugbank-id>
      <name>Cefsulodin</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13504</drugbank-id>
      <name>Cefetamet</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13638</drugbank-id>
      <name>Cefbuperazone</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefbuperazone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13667</drugbank-id>
      <name>Cefozopran</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefozopran is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13682</drugbank-id>
      <name>Cefpirome</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13778</drugbank-id>
      <name>Cefazedone</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazedone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13821</drugbank-id>
      <name>Ceftezole</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftezole is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13868</drugbank-id>
      <name>Adefovir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Inotersen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium citrate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium carbonate is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The risk or severity of nephrotoxicity and hypocalcemia can be increased when Givosiran is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Alendronic acid is combined with Clodronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Alendronic acid is combined with Etidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Alendronic acid is combined with Tiludronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06255</drugbank-id>
      <name>Incadronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Alendronic acid is combined with Incadronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00052</drugbank-id>
      <name>Somatotropin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Simvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Stavudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00666</drugbank-id>
      <name>Nafarelin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Nafarelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Naltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Lamivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Eprosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Risedronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Triazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Salmeterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Methyldopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Isotretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ganciclovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Letrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06693</drugbank-id>
      <name>Mevastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mevastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06817</drugbank-id>
      <name>Raltegravir</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Raltegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Pitavastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08983</drugbank-id>
      <name>Etofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Etofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09055</drugbank-id>
      <name>Acipimox</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Acipimox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09064</drugbank-id>
      <name>Ciprofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ciprofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ubidecarenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ipecac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13393</drugbank-id>
      <name>Emetine</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Emetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13433</drugbank-id>
      <name>Simfibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Simfibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13460</drugbank-id>
      <name>Ronifibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ronifibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13780</drugbank-id>
      <name>Aluminium clofibrate</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Aluminium clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13849</drugbank-id>
      <name>Clofibride</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Clofibride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fenofibric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05829</drugbank-id>
      <name>Parathyroid hormone</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Nitroprusside can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06783</drugbank-id>
      <name>Prussian blue</name>
      <description>Prussian blue can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09146</drugbank-id>
      <name>Iron sucrose</name>
      <description>Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09501</drugbank-id>
      <name>Ferric ammonium citrate</name>
      <description>Ferric ammonium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09507</drugbank-id>
      <name>Ferumoxsil</name>
      <description>Ferumoxsil can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09508</drugbank-id>
      <name>Ferumoxides</name>
      <description>Ferumoxides can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11171</drugbank-id>
      <name>Ferric sulfate</name>
      <description>Ferric sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11210</drugbank-id>
      <name>Ferrous bisglycinate</name>
      <description>Ferrous bisglycinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11417</drugbank-id>
      <name>Gleptoferron</name>
      <description>Gleptoferron can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11576</drugbank-id>
      <name>Ferric oxide</name>
      <description>Ferric oxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12208</drugbank-id>
      <name>Iron isomaltoside 1000</name>
      <description>Iron isomaltoside 1000 can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12821</drugbank-id>
      <name>Perflubutane</name>
      <description>Perflubutane can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13257</drugbank-id>
      <name>Ferrous sulfate anhydrous</name>
      <description>Ferrous sulfate anhydrous can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13381</drugbank-id>
      <name>Sodium feredetate</name>
      <description>Sodium feredetate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13423</drugbank-id>
      <name>Ferric hydroxide</name>
      <description>Ferric hydroxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13569</drugbank-id>
      <name>Ferrous chloride</name>
      <description>Ferrous chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13949</drugbank-id>
      <name>Ferric cation</name>
      <description>Ferric cation can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14488</drugbank-id>
      <name>Ferrous gluconate</name>
      <description>Ferrous gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14489</drugbank-id>
      <name>Ferrous succinate</name>
      <description>Ferrous succinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14491</drugbank-id>
      <name>Ferrous fumarate</name>
      <description>Ferrous fumarate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14520</drugbank-id>
      <name>Tetraferric tricitrate decahydrate</name>
      <description>Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14695</drugbank-id>
      <name>Ferric oxyhydroxide</name>
      <description>Ferric oxyhydroxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.69e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-4.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>alendronate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>249.096</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>249.016724799</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NCCCC(O)(P(O)(O)=O)P(O)(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C4H13NO7P2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OGSPWJRAVKPPFI-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>161.31</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>47.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>19.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>0.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>235</value>
      <source>https://www.tcichemicals.com/eshop/en/us/commodity/A2120/</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>2.72 (at 25 Â°C)</value>
      <source>MERCK INDEX (1996)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13353</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>2567</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>2088</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507199</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07752</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>2004</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>25313</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448082</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>212</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000182</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alendronate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL870</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/alendron.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/alendronate.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000095</smpdb-id>
      <name>Alendronate Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00169</drugbank-id>
          <name>Cholecalciferol</name>
        </drug>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00630</drugbank-id>
          <name>Alendronic acid</name>
        </drug>
        <drug>
          <drugbank-id>DB01378</drugbank-id>
          <name>Magnesium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB01592</drugbank-id>
          <name>Iron</name>
        </drug>
        <drug>
          <drugbank-id>DB01785</drugbank-id>
          <name>Dimethylallyl Diphosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB01942</drugbank-id>
          <name>Formic acid</name>
        </drug>
        <drug>
          <drugbank-id>DB02552</drugbank-id>
          <name>Geranyl Diphosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB02577</drugbank-id>
          <name>Mesoheme</name>
        </drug>
        <drug>
          <drugbank-id>DB03147</drugbank-id>
          <name>Flavin adenine dinucleotide</name>
        </drug>
        <drug>
          <drugbank-id>DB03796</drugbank-id>
          <name>Palmitic Acid</name>
        </drug>
        <drug>
          <drugbank-id>DB04160</drugbank-id>
          <name>Pyrophosphoric acid</name>
        </drug>
        <drug>
          <drugbank-id>DB04540</drugbank-id>
          <name>Cholesterol</name>
        </drug>
        <drug>
          <drugbank-id>DB04714</drugbank-id>
          <name>ISOPENTENYL PYROPHOSPHATE</name>
        </drug>
        <drug>
          <drugbank-id>DB07780</drugbank-id>
          <name>Farnesyl diphosphate</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P14324</uniprot-id>
        <uniprot-id>Q9BWD1</uniprot-id>
        <uniprot-id>Q01581</uniprot-id>
        <uniprot-id>Q03426</uniprot-id>
        <uniprot-id>Q15126</uniprot-id>
        <uniprot-id>P53602</uniprot-id>
        <uniprot-id>Q13907</uniprot-id>
        <uniprot-id>O95749</uniprot-id>
        <uniprot-id>P37268</uniprot-id>
        <uniprot-id>Q14534</uniprot-id>
        <uniprot-id>P48449</uniprot-id>
        <uniprot-id>Q15392</uniprot-id>
        <uniprot-id>Q16850</uniprot-id>
        <uniprot-id>O76062</uniprot-id>
        <uniprot-id>Q15800</uniprot-id>
        <uniprot-id>Q15738</uniprot-id>
        <uniprot-id>P56937</uniprot-id>
        <uniprot-id>Q15125</uniprot-id>
        <uniprot-id>O75845</uniprot-id>
        <uniprot-id>P04035</uniprot-id>
        <uniprot-id>P35610</uniprot-id>
        <uniprot-id>P38571</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000776</id>
      <name>Farnesyl pyrophosphate synthase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4476</ref-id>
            <pubmed-id>10620343</pubmed-id>
            <citation>Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A4477</ref-id>
            <pubmed-id>11160603</pubmed-id>
            <citation>Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.</citation>
          </article>
          <article>
            <ref-id>A4796</ref-id>
            <pubmed-id>17535895</pubmed-id>
            <citation>Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH: Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14324" source="Swiss-Prot">
        <name>Farnesyl pyrophosphate synthase</name>
        <general-function>Poly(a) rna binding</general-function>
        <specific-function>Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.</specific-function>
        <gene-name>FDPS</gene-name>
        <locus>1q22</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.8</theoretical-pi>
        <molecular-weight>48275.03</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3631</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FDPS</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J05262</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>644</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14324</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FPPS_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(2E,6E)-farnesyl diphosphate synthase</synonym>
          <synonym>2.5.1.10</synonym>
          <synonym>Dimethylallyltranstransferase</synonym>
          <synonym>Farnesyl diphosphate synthase</synonym>
          <synonym>FPP synthase</synonym>
          <synonym>FPS</synonym>
          <synonym>Geranyltranstransferase</synonym>
          <synonym>KIAA1293</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037073|Farnesyl pyrophosphate synthase
MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCWCQAWTEEPRA
LCSSLRMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAI
GGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRG
QICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLD
LLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLE
MGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKE
AEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010549|Farnesyl pyrophosphate synthase (FDPS)
ATGCCCCTGTCCCGCTGGTTGAGATCTGTGGGGGTCTTCCTGCTGCCAGCCCCCTACTGG
GCACCCCGGGAGAGGTGGCTGGGTTCCCTACGGCGGCCCTCCCTGGTGCACGGGTACCCA
GTCCTGGCCTGGCACAGTGCCCGCTGCTGGTGCCAAGCGTGGACAGAGGAACCTCGAGCC
CTTTGCTCCTCCCTCAGAATGAACGGAGACCAGAATTCAGATGTTTATGCCCAAGAAAAG
CAGGATTTCGTTCAGCACTTCTCCCAGATCGTTAGGGTGCTGACTGAGGATGAGATGGGG
CACCCAGAGATAGGAGATGCTATTGCCCGGCTCAAGGAGGTCCTGGAGTACAATGCCATT
GGAGGCAAGTATAACCGGGGTTTGACGGTGGTAGTAGCATTCCGGGAGCTGGTGGAGCCA
AGGAAACAGGATGCTGATAGTCTCCAGCGGGCCTGGACTGTGGGCTGGTGTGTGGAACTG
CTGCAAGCTTTCTTCCTGGTGGCAGATGACATCATGGATTCATCCCTTACCCGCCGGGGA
CAGATCTGCTGGTATCAGAAGCCGGGCGTGGGTTTGGATGCCATCAATGATGCTAACCTC
CTGGAAGCATGTATCTACCGCCTGCTGAAGCTCTATTGCCGGGAGCAGCCCTATTACCTG
AACCTGATCGAGCTCTTCCTGCAGAGTTCCTATCAGACTGAGATTGGGCAGACCCTGGAC
CTCCTCACAGCCCCCCAGGGCAATGTGGATCTTGTCAGATTCACTGAAAAGAGGTACAAA
TCTATTGTCAAGTACAAGACAGCTTTCTACTCCTTCTACCTTCCTATAGCTGCAGCCATG
TACATGGCAGGAATTGATGGCGAGAAGGAGCACGCCAATGCCAAGAAGATCCTGCTGGAG
ATGGGGGAGTTCTTTCAGATTCAGGATGATTACCTTGACCTCTTTGGGGACCCCAGTGTG
ACCGGCAAAATTGGCACTGACATCCAGGACAACAAATGCAGCTGGCTGGTGGTTCAGTGT
CTGCAACGGGCCACTCCAGAACAGTACCAGATCCTGAAGGAAAATTACGGGCAGAAGGAG
GCTGAGAAAGTGGCCCGGGTGAAGGCGCTATATGAGGAGCTGGATCTGCCAGCAGTGTTC
TTGCAATATGAGGAAGACAGTTACAGCCACATTATGGCTCTCATTGAACAGTACGCAGCA
CCCCTGCCCCCAGCCGTCTTTCTGGGGCTTGCGCGCAAAATCTACAAGCGGAGAAAGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00348</identifier>
            <name>polyprenyl_synt</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dimethylallyltranstransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>geranyltranstransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>poly(A) RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>farnesyl diphosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>geranyl diphosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0004801</id>
      <name>Hydroxylapatite</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15363</ref-id>
            <pubmed-id>20209564</pubmed-id>
            <citation>Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016.</citation>
          </article>
          <article>
            <ref-id>A11350</ref-id>
            <pubmed-id>16046206</pubmed-id>
            <citation>Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
    <target position="3">
      <id>BE0000980</id>
      <name>Tyrosine-protein phosphatase non-receptor type 4</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12003</ref-id>
            <pubmed-id>9310349</pubmed-id>
            <citation>Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P29074" source="Swiss-Prot">
        <name>Tyrosine-protein phosphatase non-receptor type 4</name>
        <general-function>Non-membrane spanning protein tyrosine phosphatase activity</general-function>
        <specific-function>May act at junctions between the membrane and the cytoskeleton.</specific-function>
        <gene-name>PTPN4</gene-name>
        <locus>2q14.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.47</theoretical-pi>
        <molecular-weight>105910.315</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9656</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTPN4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M68941</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>190748</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29074</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PTN4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.3.48</synonym>
          <synonym>MEG</synonym>
          <synonym>Protein-tyrosine phosphatase MEG1</synonym>
          <synonym>PTPase-MEG1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010687|Tyrosine-protein phosphatase non-receptor type 4
MTSRFRLPAGRTYNVRASELARDRQHTEVVCNILLLDNTVQAFKVNKHDQGQVLLDVVFK
HLDLTEQDYFGLQLADDSTDNPRWLDPNKPIRKQLKRGSPYSLNFRVKFFVSDPNKLQEE
YTRYQYFLQIKQDILTGRLPCPSNTAALLASFAVQSELGDYDQSENLSGYLSDYSFIPNQ
PQDFEKEIAKLHQQHIGLSPAEAEFNYLNTARTLELYGVEFHYARDQSNNEIMIGVMSGG
ILIYKNRVRMNTFPWLKIVKISFKCKQFFIQLRKELHESRETLLGFNMVNYRACKNLWKA
CVEHHTFFRLDRPLPPQKNFFAHYFTLGSKFRYCGRTEVQSVQYGKEKANKDRVFARSPS
KPLARKLMDWEVVSRNSISDDRLETQSLPSRSPPGTPNHRNSTFTQEGTRLRPSSVGHLV
DHMVHTSPSEVFVNQRSPSSTQANSIVLESSPSQETPGDGKPPALPPKQSKKNSWNQIHY
SHSQQDLESHINETFDIPSSPEKPTPNGGIPHDNLVLIRMKPDENGRFGFNVKGGYDQKM
PVIVSRVAPGTPADLCVPRLNEGDQVVLINGRDIAEHTHDQVVLFIKASCERHSGELMLL
VRPNAVYDVVEEKLENEPDFQYIPEKAPLDSVHQDDHSLRESMIQLAEGLITGTVLTQFD
QLYRKKPGMTMSCAKLPQNISKNRYRDISPYDATRVILKGNEDYINANYINMEIPSSSII
NQYIACQGPLPHTCTDFWQMTWEQGSSMVVMLTTQVERGRVKCHQYWPEPTGSSSYGCYQ
VTCHSEEGNTAYIFRKMTLFNQEKNESRPLTQIQYIAWPDHGVPDDSSDFLDFVCHVRNK
RAGKEEPVVVHCSAGIGRTGVLITMETAMCLIECNQPVYPLDIVRTMRDQRAMMIQTPSQ
YRFVCEAILKVYEEGFVKPLTTSTNK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010688|Tyrosine-protein phosphatase non-receptor type 4 (PTPN4)
ATGACCTCACGTTTCCGATTGCCTGCTGGCAGAACCTACAATGTACGAGCATCAGAGTTG
GCCCGAGACAGACAGCATACTGAAGTGGTTTGCAACATCCTTCTTCTGGATAACACTGTA
CAAGCTTTCAAAGTCAATAAACATGATCAGGGGCAAGTCTTGTTGGATGTCGTCTTCAAG
CATCTAGATTTGACTGAGCAGGACTATTTTGGTTTACAGTTGGCTGATGATTCCACAGAT
AACCCAAGGTGGCTGGATCCAAACAAACCAATAAGGAAGCAGCTAAAGAGAGGATCTCCT
TACAGTTTGAACTTTAGAGTCAAATTTTTTGTAAGTGACCCCAACAAGTTACAAGAAGAA
TATACAAGGTACCAGTATTTTTTGCAAATTAAACAAGACATTCTTACTGGAAGATTACCC
TGTCCTTCTAATACTGCTGCCCTTTTAGCTTCATTTGCTGTTCAGTCTGAACTTGGAGAC
TACGATCAGTCAGAGAACTTGTCAGGCTACCTCTCAGATTATTCTTTCATTCCTAATCAA
CCTCAAGATTTTGAAAAAGAAATTGCAAAATTACATCAGCAACACATAGGCTTATCTCCT
GCAGAAGCAGAATTTAATTACCTAAACACAGCACGTACCTTAGAACTCTATGGAGTTGAA
TTCCACTATGCAAGGGATCAGAGTAACAATGAAATTATGATTGGAGTGATGTCAGGAGGA
ATTCTGATTTATAAGAACAGGGTACGAATGAATACCTTTCCATGGTTGAAGATTGTAAAA
ATTTCTTTTAAGTGCAAACAGTTTTTTATTCAACTTAGAAAAGAATTGCATGAATCTAGA
GAAACATTATTGGGATTTAATATGGTGAATTACAGAGCATGTAAAAATTTGTGGAAAGCA
TGTGTAGAACATCACACATTCTTCCGTTTGGACAGACCACTTCCACCTCAAAAGAATTTT
TTTGCACATTATTTTACATTAGGTTCAAAATTCCGGTACTGTGGGAGAACTGAAGTCCAA
TCAGTTCAGTATGGCAAAGAAAAGGCAAATAAAGACAGGGTATTTGCAAGATCCCCAAGT
AAGCCCTTGGCACGGAAATTAATGGATTGGGAAGTAGTAAGCAGAAATTCAATATCTGAT
GACAGGTTAGAAACACAAAGTCTTCCATCACGATCTCCACCGGGAACTCCTAATCATCGA
AATTCTACATTCACGCAGGAAGGAACCCGGTTACGACCATCTTCAGTTGGTCATTTGGTA
GACCATATGGTTCATACTTCCCCAAGCGAAGTGTTTGTAAATCAGAGATCTCCGTCATCA
ACACAAGCTAATAGCATTGTTCTGGAATCATCACCATCACAAGAGACCCCTGGAGATGGG
AAGCCTCCAGCTTTACCACCCAAACAGTCAAAGAAAAACAGTTGGAACCAAATTCATTAT
TCACATTCGCAACAAGATCTAGAAAGTCATATTAATGAAACATTTGATATTCCATCTTCT
CCTGAAAAACCCACTCCTAATGGTGGTATTCCACATGATAATCTTGTCCTAATCAGAATG
AAACCTGATGAAAATGGGAGGTTTGGATTCAATGTAAAGGGAGGATATGATCAGAAGATG
CCTGTGATTGTGTCTCGAGTAGCACCAGGAACACCTGCTGACCTCTGTGTCCCTAGACTG
AATGAAGGGGACCAAGTTGTACTGATCAATGGTCGGGACATTGCAGAACACACTCATGAT
CAGGTTGTGCTGTTTATTAAAGCTAGTTGTGAGAGACATTCTGGGGAACTCATGCTTCTA
GTTCGACCTAATGCTGTATATGATGTAGTGGAAGAAAAGCTAGAAAATGAGCCAGATTTC
CAGTATATTCCTGAGAAAGCCCCACTAGATAGTGTGCATCAGGATGACCATTCCCTGCGG
GAGTCAATGATCCAGCTAGCTGAGGGGCTTATCACTGGAACAGTCCTGACACAGTTTGAT
CAACTGTATCGGAAAAAACCTGGAATGACAATGTCCTGTGCCAAATTACCTCAGAATATT
TCCAAAAATAGATACAGAGATATTTCGCCTTATGATGCCACACGGGTCATTTTAAAAGGT
AATGAAGACTACATCAATGCGAACTATATAAATATGGAAATTCCTTCTTCCAGCATTATA
AATCAGTACATTGCTTGTCAAGGGCCATTACCACACACTTGTACAGATTTTTGGCAGATG
ACTTGGGAACAAGGCTCCTCTATGGTTGTAATGTTGACCACACAAGTTGAACGTGGCAGA
GTTAAATGTCACCAATATTGGCCAGAACCCACAGGCAGTTCATCTTATGGATGCTACCAA
GTTACCTGCCACTCTGAAGAAGGAAACACTGCCTATATCTTCAGGAAGATGACCCTATTT
AACCAAGAGAAAAATGAAAGTCGTCCACTCACTCAGATCCAGTACATAGCCTGGCCTGAC
CATGGAGTCCCTGATGATTCGAGTGACTTTCTAGATTTTGTTTGTCATGTACGAAACAAG
AGGGCTGGCAAGGAAGAACCCGTTGTTGTCCATTGCAGTGCTGGAATCGGAAGAACTGGG
GTTCTTATTACTATGGAAACAGCCATGTGTCTCATTGAATGCAATCAGCCAGTTTATCCA
CTAGATATTGTAAGAACAATGAGAGATCAGCGAGCCATGATGATCCAAACACCTAGTCAA
TACAGATTTGTATGTGAAGCTATTTTGAAAGTTTATGAAGAAGGCTTTGTTAAACCCTTA
ACAACATCAACAAATAAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00595</identifier>
            <name>PDZ</name>
          </pfam>
          <pfam>
            <identifier>PF00102</identifier>
            <name>Y_phosphatase</name>
          </pfam>
          <pfam>
            <identifier>PF00373</identifier>
            <name>FERM_M</name>
          </pfam>
          <pfam>
            <identifier>PF08736</identifier>
            <name>FA</name>
          </pfam>
          <pfam>
            <identifier>PF09380</identifier>
            <name>FERM_C</name>
          </pfam>
          <pfam>
            <identifier>PF09379</identifier>
            <name>FERM_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>non-membrane spanning protein tyrosine phosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein dephosphorylation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0003567</id>
      <name>Receptor-type tyrosine-protein phosphatase S</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12003</ref-id>
            <pubmed-id>9310349</pubmed-id>
            <citation>Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A: Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997 Sep 15;54(6):721-7.</citation>
          </article>
          <article>
            <ref-id>A15351</ref-id>
            <pubmed-id>8610169</pubmed-id>
            <citation>Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q13332" source="Swiss-Prot">
        <name>Receptor-type tyrosine-protein phosphatase S</name>
        <general-function>Transmembrane receptor protein tyrosine phosphatase activity</general-function>
        <specific-function>Interacts with LAR-interacting protein LIP.1.</specific-function>
        <gene-name>PTPRS</gene-name>
        <locus>19p13.3</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1283-1303</transmembrane-regions>
        <signal-regions>1-29</signal-regions>
        <theoretical-pi>6.46</theoretical-pi>
        <molecular-weight>217039.825</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9681</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U35234</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1109792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1866</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13332</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PTPRS_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.3.48</synonym>
          <synonym>R-PTP-S</synonym>
          <synonym>R-PTP-sigma</synonym>
          <synonym>Receptor-type tyrosine-protein phosphatase sigma</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037247|Receptor-type tyrosine-protein phosphatase S
MAPTWGPGMVSVVGPMGLLVVLLVGGCAAEEPPRFIKEPKDQIGVSGGVASFVCQATGDP
KPRVTWNKKGKKVNSQRFETIEFDESAGAVLRIQPLRTPRDENVYECVAQNSVGEITVHA
KLTVLREDQLPSGFPNIDMGPQLKVVERTRTATMLCAASGNPDPEITWFKDFLPVDPSAS
NGRIKQLRSETFESTPIRGALQIESSEETDQGKYECVATNSAGVRYSSPANLYVRELREV
RRVAPRFSILPMSHEIMPGGNVNITCVAVGSPMPYVKWMQGAEDLTPEDDMPVGRNVLEL
TDVKDSANYTCVAMSSLGVIEAVAQITVKSLPKAPGTPMVTENTATSITITWDSGNPDPV
SYYVIEYKSKSQDGPYQIKEDITTTRYSIGGLSPNSEYEIWVSAVNSIGQGPPSESVVTR
TGEQAPASAPRNVQARMLSATTMIVQWEEPVEPNGLIRGYRVYYTMEPEHPVGNWQKHNV
DDSLLTTVGSLLEDETYTVRVLAFTSVGDGPLSDPIQVKTQQGVPGQPMNLRAEARSETS
ITLSWSPPRQESIIKYELLFREGDHGREVGRTFDPTTSYVVEDLKPNTEYAFRLAARSPQ
GLGAFTPVVRQRTLQSKPSAPPQDVKCVSVRSTAILVSWRPPPPETHNGALVGYSVRYRP
LGSEDPEPKEVNGIPPTTTQILLEALEKWTQYRITTVAHTEVGPGPESSPVVVRTDEDVP
SAPPRKVEAEALNATAIRVLWRSPAPGRQHGQIRGYQVHYVRMEGAEARGPPRIKDVMLA
DAQWETDDTAEYEMVITNLQPETAYSITVAAYTMKGDGARSKPKVVVTKGAVLGRPTLSV
QQTPEGSLLARWEPPAGTAEDQVLGYRLQFGREDSTPLATLEFPPSEDRYTASGVHKGAT
YVFRLAARSRGGLGEEAAEVLSIPEDTPRGHPQILEAAGNASAGTVLLRWLPPVPAERNG
AIVKYTVAVREAGALGPARETELPAAAEPGAENALTLQGLKPDTAYDLQVRAHTRRGPGP
FSPPVRYRTFLRDQVSPKNFKVKMIMKTSVLLSWEFPDNYNSPTPYKIQYNGLTLDVDGR
TTKKLITHLKPHTFYNFVLTNRGSSLGGLQQTVTAWTAFNLLNGKPSVAPKPDADGFIMV
YLPDGQSPVPVQSYFIVMVPLRKSRGGQFLTPLGSPEDMDLEELIQDISRLQRRSLRHSR
QLEVPRPYIAARFSVLPPTFHPGDQKQYGGFDNRGLEPGHRYVLFVLAVLQKSEPTFAAS
PFSDPFQLDNPDPQPIVDGEEGLIWVIGPVLAVVFIICIVIAILLYKNKPDSKRKDSEPR
TKCLLNNADLAPHHPKDPVEMRRINFQTPDSGLRSPLREPGFHFESMLSHPPIPIADMAE
HTERLKANDSLKLSQEYESIDPGQQFTWEHSNLEVNKPKNRYANVIAYDHSRVILQPIEG
IMGSDYINANYVDGYRCQNAYIATQGPLPETFGDFWRMVWEQRSATIVMMTRLEEKSRIK
CDQYWPNRGTETYGFIQVTLLDTIELATFCVRTFSLHKNGSSEKREVRQFQFTAWPDHGV
PEYPTPFLAFLRRVKTCNPPDAGPIVVHCSAGVGRTGCFIVIDAMLERIKPEKTVDVYGH
VTLMRSQRNYMVQTEDQYSFIHEALLEAVGCGNTEVPARSLYAYIQKLAQVEPGEHVTGM
ELEFKRLANSKAHTSRFISANLPCNKFKNRLVNIMPYESTRVCLQPIRGVEGSDYINASF
IDGYRQQKAYIATQGPLAETTEDFWRMLWENNSTIVVMLTKLREMGREKCHQYWPAERSA
RYQYFVVDPMAEYNMPQYILREFKVTDARDGQSRTVRQFQFTDWPEQGVPKSGEGFIDFI
GQVHKTKEQFGQDGPISVHCSAGVGRTGVFITLSIVLERMRYEGVVDIFQTVKMLRTQRP
AMVQTEDEYQFCYQAALEYLGSFDHYAT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019440|Receptor-type tyrosine-protein phosphatase S (PTPRS)
ATGGCGCCCACCTGGGGCCCTGGCATGGTGTCTGTGGTTGGTCCCATGGGCCTCCTTGTG
GTCCTGCTCGTTGGAGGCTGTGCAGCAGAAGAGCCCCCCAGGTTTATCAAAGAACCCAAG
GACCAGATCGGCGTGTCGGGGGGTGTGGCCTCTTTCGTGTGTCAGGCCACGGGTGACCCC
AAGCCACGAGTGACCTGGAACAAGAAGGGCAAGAAGGTCAACTCTCAGCGCTTTGAGACG
ATTGAGTTTGATGAGAGTGCAGGGGCAGTGCTGAGGATCCAGCCGCTGAGGACACCGCGG
GATGAAAACGTGTACGAGTGTGTGGCCCAGAACTCGGTTGGGGAGATCACAGTCCATGCC
AAGCTTACTGTCCTCCGAGAGGACCAGCTGCCCTCTGGCTTCCCCAACATCGACATGGGC
CCACAGTTGAAGGTGGTGGAGCGGACACGGACAGCCACCATGCTCTGTGCAGCCAGCGGC
AACCCTGACCCTGAGATCACCTGGTTCAAGGACTTCCTGCCTGTGGATCCTAGTGCCAGC
AATGGACGCATCAAACAGCTGCGATCAGAAACCTTTGAAAGCACTCCGATTCGAGGAGCC
CTGCAGATTGAAAGCAGTGAGGAAACCGACCAGGGCAAATATGAGTGTGTGGCCACCAAC
AGCGCCGGCGTGCGCTACTCCTCACCTGCCAACCTCTACGTGCGAGAGCTTCGAGAAGTC
CGCCGCGTGGCCCCGCGCTTCTCCATCCTGCCCATGAGCCACGAGATCATGCCAGGGGGC
AACGTGAACATCACCTGCGTGGCCGTGGGCTCGCCCATGCCATACGTGAAGTGGATGCAG
GGGGCCGAGGACCTGACCCCCGAGGATGACATGCCCGTGGGTCGGAACGTGCTGGAACTC
ACAGATGTCAAGGACTCGGCCAACTACACCTGCGTGGCCATGTCCAGCCTGGGCGTCATT
GAGGCGGTTGCTCAGATCACGGTGAAATCTCTCCCCAAAGCTCCCGGGACTCCCATGGTG
ACTGAGAACACAGCCACCAGCATCACCATCACGTGGGACTCGGGCAACCCAGATCCTGTG
TCCTATTACGTCATCGAATATAAATCCAAGAGCCAAGACGGGCCGTATCAGATTAAAGAG
GACATCACCACCACACGTTACAGCATCGGCGGCCTGAGCCCCAACTCGGAGTACGAGATC
TGGGTGTCGGCCGTCAACTCCATCGGCCAGGGGCCCCCCAGCGAGTCCGTGGTCACCCGC
ACAGGCGAGCAGGCCCCGGCCAGCGCGCCGCGGAACGTGCAAGCCCGGATGCTCAGCGCG
ACCACCATGATTGTGCAGTGGGAGGAGCCGGTGGAGCCCAACGGCCTGATCCGCGGCTAC
CGCGTCTACTACACCATGGAACCGGAGCACCCCGTGGGCAACTGGCAGAAGCACAACGTG
GACGACAGCCTGCTGACCACCGTGGGCAGCCTGCTGGAGGACGAGACCTACACCGTGCGG
GTGCTCGCCTTCACCTCCGTCGGCGACGGGCCCCTCTCGGACCCCATCCAGGTCAAGACG
CAGCAGGGAGTGCCGGGCCAGCCCATGAACCTGCGGGCCGAGGCCAGGTCGGAGACCAGC
ATCACGCTGTCCTGGAGCCCCCCGCGGCAGGAGAGTATCATCAAGTACGAGCTCCTCTTC
CGGGAAGGCGACCATGGCCGGGAGGTGGGAAGGACCTTCGACCCGACGACTTCCTACGTG
GTGGAGGACCTGAAGCCCAACACGGAGTACGCCTTCCGCCTGGCGGCCCGCTCGCCGCAG
GGCCTGGGCGCCTTCACCCCCGTGGTGCGGCAGCGCACGCTGCAGTCCAAACCGTCAGCC
CCCCCTCAAGACGTTAAATGTGTCAGCGTGCGCTCCACGGCCATTTTGGTAAGTTGGCGC
CCGCCGCCGCCGGAAACGCACAACGGGGCCCTGGTGGGCTACAGCGTCCGCTACCGACCG
CTGGGCTCAGAGGACCCGGAACCCAAGGAGGTGAACGGCATCCCCCCGACCACCACTCAG
ATCCTGCTGGAGGCCTTGGAGAAGTGGACCCAGTACCGCATCACGACTGTCGCTCACACA
GAGGTGGGACCAGGGCCCGAGAGCTCGCCCGTGGTCGTCCGCACCGACGAGGATGTGCCC
AGCGCGCCGCCGCGGAAGGTGGAGGCGGAGGCGCTCAACGCCACGGCCATCCGCGTGCTG
TGGCGCTCGCCCGCGCCCGGCCGGCAGCACGGCCAGATCCGCGGCTACCAGGTCCACTAC
GTGCGCATGGAGGGCGCCGAGGCCCGCGGGCCGCCGCGCATCAAGGACGTCATGCTGGCC
GATGCCCAGTGGGAGACGGATGACACGGCCGAATATGAGATGGTCATCACAAACTTGCAG
CCTGAGACCGCGTACTCCATCACGGTAGCCGCCTACACCATGAAGGGCGATGGCGCTCGC
AGCAAACCCAAGGTGGTTGTGACCAAGGGAGCAGTGCTGGGCCGCCCAACCCTGTCGGTG
CAGCAGACCCCCGAGGGCAGCCTGCTGGCACGCTGGGAGCCCCCGGCTGGCACCGCGGAG
GACCAGGTGCTGGGCTACCGCCTGCAGTTTGGCCGTGAGGACTCGACGCCCCTGGCCACC
CTGGAGTTCCCGCCCTCCGAGGACCGCTACACGGCATCAGGCGTGCACAAGGGGGCCACG
TATGTGTTCCGGCTTGCGGCCCGGAGCCGCGGCGGCCTGGGCGAGGAGGCAGCCGAGGTC
CTGAGCATCCCGGAGGACACGCCCCGTGGCCACCCGCAGATTCTGGAGGCGGCCGGCAAC
GCCTCGGCCGGGACCGTCCTTCTCCGCTGGCTGCCACCCGTGCCCGCCGAGCGCAACGGG
GCCATCGTCAAATACACGGTGGCCGTGCGGGAGGCCGGTGCCCTGGGCCCTGCCCGAGAG
ACTGAGCTGCCGGCAGCGGCTGAGCCGGGCGCGGAGAACGCGCTCACGCTGCAGGGCCTG
AAGCCCGACACGGCCTATGACCTCCAAGTGCGAGCCCACACGCGCCGGGGCCCTGGCCCC
TTCAGCCCCCCCGTCCGCTACCGGACGTTCCTGCGGGACCAAGTCTCGCCCAAGAACTTC
AAGGTGAAAATGATCATGAAGACATCAGTTCTGCTCAGCTGGGAGTTCCCTGACAACTAC
AACTCACCCACACCCTACAAGATCCAGTACAATGGGCTCACACTGGATGTGGATGGCCGT
ACCACCAAGAAGCTCATCACGCACCTCAAGCCCCACACCTTCTACAACTTTGTGCTGACC
AATCGCGGCAGCAGCCTGGGCGGCCTCCAGCAGACGGTCACCGCCTGGACTGCCTTCAAC
CTGCTCAACGGCAAGCCCAGCGTCGCCCCCAAGCCTGATGCTGACGGCTTCATCATGGTG
TATCTTCCTGACGGCCAGAGCCCCGTGCCTGTCCAGAGCTATTTCATTGTGATGGTGCCA
CTGCGCAAGTCTCGTGGAGGCCAATTCCTGACCCCGCTGGGTAGCCCAGAGGACATGGAT
CTGGAAGAGCTCATCCAGGACATCTCACGGCTACAGAGGCGCAGCCTGCGGCACTCGCGT
CAGCTGGAGGTGCCCCGGCCCTATATTGCAGCTCGCTTCTCTGTGCTGCCACCCACGTTC
CATCCCGGCGACCAGAAGCAGTATGGCGGCTTCGATAACCGGGGCCTGGAGCCCGGCCAC
CGCTATGTCCTCTTCGTGCTTGCCGTGCTTCAGAAGAGCGAGCCTACCTTTGCAGCCAGT
CCCTTCTCAGACCCCTTCCAGCTGGATAACCCGGACCCCCAGCCCATCGTGGATGGCGAG
GAGGGGCTTATCTGGGTGATCGGGCCTGTGCTGGCCGTGGTCTTCATAATCTGCATTGTC
ATTGCTATCCTGCTCTACAAGAACAAACCCGACAGTAAACGCAAGGACTCAGAACCCCGC
ACCAAATGCCTCCTGAACAATGCCGACCTCGCCCCTCACCACCCCAAGGACCCTGTGGAA
ATGAGACGCATTAACTTCCAGACTCCAGATTCAGGCCTCAGGAGCCCCCTCAGGGAGCCG
GGGTTTCACTTTGAAAGCATGCTTAGCCACCCGCCAATTCCCATCGCAGACATGGCGGAG
CACACGGAGCGGCTCAAGGCCAACGACAGCCTCAAGCTCTCCCAGGAGTATGAGTCCATC
GACCCTGGACAGCAGTTCACATGGGAACATTCCAACCTGGAAGTGAACAAGCCGAAGAAC
CGCTATGCCAACGTCATCGCCTATGACCACTCCCGTGTCATCCTCCAGCCCATTGAAGGC
ATCATGGGCAGTGATTACATCAATGCCAACTACGTGGACGGCTACCGGTGTCAGAACGCG
TACATTGCCACGCAGGGGCCGCTGCCTGAGACCTTTGGGGACTTCTGGCGTATGGTGTGG
GAGCAGCGGTCGGCGACCATCGTCATGATGACGCGGCTGGAGGAGAAGTCACGGATCAAG
TGTGATCAGTATTGGCCCAACAGAGGCACGGAGACCTACGGCTTCATCCAGGTCACGTTG
CTAGATACCATCGAGCTGGCCACATTCTGCGTCAGGACATTCTCTCTGCACAAGAATGGC
TCCAGTGAGAAACGCGAGGTCCGCCAGTTCCAGTTTACGGCGTGGCCGGACCATGGCGTG
CCCGAATACCCAACGCCCTTCCTGGCTTTCCTGCGGAGAGTCAAGACCTGCAACCCGCCA
GATGCCGGCCCCATCGTGGTTCACTGCAGTGCCGGTGTGGGCCGCACAGGCTGCTTTATC
GTCATCGACGCCATGCTTGAGCGGATCAAGCCAGAGAAGACAGTCGATGTCTATGGCCAC
GTGACGCTCATGAGGTCCCAGCGCAACTACATGGTGCAGACGGAGGACCAGTACAGCTTC
ATCCACGAGGCCCTGCTGGAGGCCGTGGGCTGTGGCAACACAGAAGTGCCCGCACGCAGC
CTCTATGCCTACATCCAGAAGCTGGCCCAGGTGGAGCCTGGCGAACACGTCACTGGCATG
GAACTCGAGTTCAAGCGGCTGGCTAACTCCAAGGCCCACACGTCACGCTTCATCAGTGCC
AATCTGCCTTGTAACAAGTTCAAGAACCGCCTGGTGAACATCATGCCCTATGAGAGCACA
CGGGTCTGTCTGCAACCCATCCGGGGTGTGGAGGGCTCTGACTACATCAACGCCAGCTTC
ATTGATGGCTACAGGCAGCAGAAGGCCTACATCGCGACACAGGGGCCGCTGGCGGAGACC
ACGGAAGACTTCTGGCGCATGCTGTGGGAGAACAATTCGACGATCGTGGTGATGCTGACC
AAGCTGCGGGAGATGGGCCGGGAGAAGTGTCACCAGTACTGGCCGGCCGAGCGCTCTGCC
CGCTACCAGTACTTTGTGGTAGATCCGATGGCAGAATACAACATGCCTCAGTATATCCTG
CGAGAGTTCAAGGTCACAGATGCCCGGGATGGCCAGTCCCGGACTGTCCGGCAGTTCCAG
TTCACAGACTGGCCGGAACAGGGTGTGCCAAAGTCGGGGGAGGGCTTCATCGACTTCATT
GGCCAAGTGCATAAGACTAAGGAGCAGTTTGGCCAGGACGGCCCCATCTCTGTCCACTGC
AGTGCCGGCGTGGGCAGGACGGGCGTCTTCATCACGCTTAGCATCGTGCTGGAGCGGATG
CGGTATGAAGGCGTGGTGGACATCTTTCAGACGGTGAAGATGCTACGAACCCAGCGGCCG
GCCATGGTGCAGACAGAGGATGAGTACCAGTTCTGTTACCAGGCGGCACTGGAGTACCTC
GGAAGCTTTGACCACTATGCAACCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07679</identifier>
            <name>I-set</name>
          </pfam>
          <pfam>
            <identifier>PF00041</identifier>
            <name>fn3</name>
          </pfam>
          <pfam>
            <identifier>PF00102</identifier>
            <name>Y_phosphatase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane receptor protein tyrosine phosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebellum development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>corpus callosum development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment of endothelial intestinal barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hippocampus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spinal cord development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0003568</id>
      <name>Receptor-type tyrosine-protein phosphatase epsilon</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15351</ref-id>
            <pubmed-id>8610169</pubmed-id>
            <citation>Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P23469" source="Swiss-Prot">
        <name>Receptor-type tyrosine-protein phosphatase epsilon</name>
        <general-function>Transmembrane receptor protein tyrosine phosphatase activity</general-function>
        <specific-function>Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells. May play a role in osteoclast formation and function (By similarity).Isoform 2 acts as a negative regulator of insulin receptor (IR) signaling in skeletal muscle. Regulates insulin-induced tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate 1 (IRS-1), phosphorylation of protein kinase B and glycogen synthase kinase-3 and insulin induced stimulation of glucose uptake (By similarity).Isoform 1 and isoform 2 act as a negative regulator of FceRI-mediated signal transduction leading to cytokine production and degranulation, most likely by acting at the level of SYK to affect downstream events such as phosphorylation of SLP76 and LAT and mobilization of Ca(2+).</specific-function>
        <gene-name>PTPRE</gene-name>
        <locus>10q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>47-69</transmembrane-regions>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>7.02</theoretical-pi>
        <molecular-weight>80641.165</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9669</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X54134</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P23469</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PTPRE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.3.48</synonym>
          <synonym>Protein-tyrosine phosphatase epsilon</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006873|Receptor-type tyrosine-protein phosphatase epsilon
MEPLCPLLLVGFSLPLARALRGNETTADSNETTTTSGPPDPGASQPLLAWLLLPLLLLLL
VLLLAAYFFRFRKQRKAVVSTSDKKMPNGILEEQEQQRVMLLSRSPSGPKKYFPIPVEHL
EEEIRIRSADDCKQFREEFNSLPSGHIQGTFELANKEENREKNRYPNILPNDHSRVILSQ
LDGIPCSDYINASYIDGYKEKNKFIAAQGPKQETVNDFWRMVWEQKSATIVMLTNLKERK
EEKCHQYWPDQGCWTYGNIRVCVEDCVVLVDYTIRKFCIQPQLPDGCKAPRLVSQLHFTS
WPDFGVPFTPIGMLKFLKKVKTLNPVHAGPIVVHCSAGVGRTGTFIVIDAMMAMMHAEQK
VDVFEFVSRIRNQRPQMVQTDMQYTFIYQALLEYYLYGDTELDVSSLEKHLQTMHGTTTH
FDKIGLEEEFRKLTNVRIMKENMRTGNLPANMKKARVIQIIPYDFNRVILSMKRGQEYTD
YINASFIDGYRQKDYFIATQGPLAHTVEDFWRMIWEWKSHTIVMLTEVQEREQDKCYQYW
PTEGSVTHGEITIEIKNDTLSEAISIRDFLVTLNQPQARQEEQVRVVRQFHFHGWPEIGI
PAEGKGMIDLIAAVQKQQQQTGNHPITVHCSAGAGRTGTFIALSNILERVKAEGLLDVFQ
AVKSLRLQRPHMVQTLEQYEFCYKVVQDFIDIFSDYANFK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012481|Receptor-type tyrosine-protein phosphatase epsilon (PTPRE)
ATGGAGCCCTTGTGTCCACTCCTGCTGGTGGGTTTTAGCTTGCCGCTCGCCAGGGCTCTC
AGGGGCAACGAGACCACTGCCGACAGCAACGAGACAACCACGACCTCAGGCCCTCCGGAC
CCGGGCGCCTCCCAGCCGCTGCTGGCCTGGCTGCTACTGCCGCTGCTGCTCCTCCTCCTC
GTGCTCCTTCTCGCCGCCTACTTCTTCAGGTTCAGGAAGCAGAGGAAAGCTGTGGTCAGC
ACCAGCGACAAGAAGATGCCCAACGGAATCTTGGAGGAGCAAGAGCAGCAAAGGGTGATG
CTGCTCAGCAGGTCACCCTCAGGGCCCAAGAAGTATTTTCCCATCCCCGTGGAGCACCTG
GAGGAGGAGATCCGTATCAGATCCGCCGACGACTGCAAGCAGTTTCGGGAGGAGTTCAAC
TCATTGCCATCTGGACACATACAAGGAACTTTTGAACTGGCAAATAAAGAAGAAAACAGA
GAAAAAAACAGATATCCCAACATCCTTCCCAATGACCATTCTAGGGTGATTCTGAGCCAA
CTGGATGGAATTCCCTGTTCAGACTACATCAATGCTTCCTACATAGATGGTTACAAAGAG
AAGAATAAATTCATAGCAGCTCAAGGTCCCAAACAGGAAACGGTTAACGACTTCTGGAGA
ATGGTCTGGGAGCAAAAGTCTGCGACCATCGTCATGTTAACAAACTTGAAAGAAAGGAAA
GAGGAAAAGTGCCATCAGTACTGGCCCGACCAAGGCTGCTGGACCTATGGAAACATCCGG
GTGTGCGTGGAGGACTGCGTGGTTTTGGTCGACTACACCATCCGGAAGTTCTGCATACAG
CCACAGCTCCCCGACGGCTGCAAAGCCCCCAGGCTGGTCTCACAGCTGCACTTCACCAGC
TGGCCCGACTTCGGAGTGCCTTTTACCCCCATTGGGATGCTGAAGTTCCTCAAGAAAGTA
AAGACGCTCAACCCCGTGCACGCTGGGCCCATCGTGGTCCACTGTAGCGCGGGCGTGGGC
CGGACGGGCACCTTCATTGTGATCGATGCCATGATGGCCATGATGCACGCGGAGCAGAAG
GTGGATGTGTTTGAATTTGTGTCTCGAATCCGTAATCAGCGCCCTCAGATGGTTCAAACG
GATATGCAGTACACGTTCATCTACCAAGCCTTACTCGAGTACTACCTCTACGGGGACACA
GAGCTGGACGTGTCCTCCCTGGAGAAGCACCTGCAGACCATGCACGGCACCACCACCCAC
TTCGACAAGATCGGGCTGGAGGAGGAGTTCAGGAAATTGACAAATGTCCGGATCATGAAG
GAGAACATGAGGACGGGCAACTTGCCGGCAAACATGAAGAAGGCCAGGGTCATCCAGATC
ATCCCGTATGACTTCAACCGAGTGATCCTTTCCATGAAAAGGGGTCAAGAATACACAGAC
TACATCAACGCATCCTTCATAGACGGCTACCGACAGAAGGACTATTTCATCGCCACCCAG
GGGCCACTGGCACACACGGTTGAGGACTTCTGGAGGATGATCTGGGAATGGAAATCCCAC
ACTATCGTGATGCTGACGGAGGTGCAGGAGAGAGAGCAGGATAAATGCTACCAGTATTGG
CCAACCGAGGGCTCAGTTACTCATGGAGAAATAACGATTGAGATAAAGAATGATACCCTT
TCAGAAGCCATCAGTATACGAGACTTTCTGGTCACTCTCAATCAGCCCCAGGCCCGCCAG
GAGGAGCAGGTCCGAGTAGTGCGCCAGTTTCACTTCCACGGCTGGCCTGAGATCGGGATT
CCCGCCGAGGGCAAAGGCATGATTGACCTCATCGCAGCCGTGCAGAAGCAGCAGCAGCAG
ACAGGCAACCACCCCATCACCGTGCACTGCAGTGCCGGAGCTGGGCGAACAGGTACATTC
ATAGCCCTCAGCAACATTTTGGAGCGAGTAAAAGCCGAGGGACTTTTAGATGTATTTCAA
GCTGTGAAGAGTTTACGACTTCAGAGACCACATATGGTGCAAACCCTGGAACAGTATGAA
TTCTGCTACAAAGTGGTACAAGATTTTATTGATATATTTTCTGATTATGCTAATTTCAAA
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00102</identifier>
            <name>Y_phosphatase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane receptor protein tyrosine phosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of mast cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane receptor protein tyrosine phosphatase signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0003569</id>
      <name>V-type proton ATPase catalytic subunit A</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15353</ref-id>
            <pubmed-id>8889850</pubmed-id>
            <citation>David P, Nguyen H, Barbier A, Baron R: The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996 Oct;11(10):1498-507.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P38606" source="Swiss-Prot">
        <name>V-type proton ATPase catalytic subunit A</name>
        <general-function>Proton-transporting atpase activity, rotational mechanism</general-function>
        <specific-function>Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.</specific-function>
        <gene-name>ATP6V1A</gene-name>
        <locus>3q13.2-q13.31</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.16</theoretical-pi>
        <molecular-weight>68303.5</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:851</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L09235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>291868</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P38606</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>VATA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.14</synonym>
          <synonym>ATP6A1</synonym>
          <synonym>ATP6V1A1</synonym>
          <synonym>V-ATPase 69 kDa subunit</synonym>
          <synonym>V-ATPase subunit A</synonym>
          <synonym>Vacuolar ATPase isoform VA68</synonym>
          <synonym>Vacuolar proton pump subunit alpha</synonym>
          <synonym>VPP2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006875|V-type proton ATPase catalytic subunit A
MDFSKLPKILDEDKESTFGYVHGVSGPVVTACDMAGAAMYELVRVGHSELVGEIIRLEGD
MATIQVYEETSGVSVGDPVLRTGKPLSVELGPGIMGAIFDGIQRPLSDISSQTQSIYIPR
GVNVSALSRDIKWDFTPCKNLRVGSHITGGDIYGIVSENSLIKHKIMLPPRNRGTVTYIA
PPGNYDTSDVVLELEFEGVKEKFTMVQVWPVRQVRPVTEKLPANHPLLTGQRVLDALFPC
VQGGTTAIPGAFGCGKTVISQSLSKYSNSDVIIYVGCGERGNEMSEVLRDFPELTMEVDG
KVESIMKRTALVANTSNMPVAAREASIYTGITLSEYFRDMGYHVSMMADSTSRWAEALRE
ISGRLAEMPADSGYPAYLGARLASFYERAGRVKCLGNPEREGSVSIVGAVSPPGGDFSDP
VTSATLGIVQVFWGLDKKLAQRKHFPSVNWLISYSKYMRALDEYYDKHFTEFVPLRTKAK
EILQEEEDLAEIVQLVGKASLAETDKITLEVAKLIKDDFLQQNGYTPYDRFCPFYKTVGM
LSNMIAFYDMARRAVETTAQSDNKITWSIIREHMGDILYKLSSMKFKDPLKDGEAKIKSD
YAQLLEDMQNAFRSLED</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012482|V-type proton ATPase catalytic subunit A (ATP6V1A)
ATGGATTTTTCCAAGCTACCCAAAATACTCGATGAAGATAAAGAAAGCACATTTGGTTAT
GTGCATGGGGTCTCAGGACCTGTGGTTACAGCCTGTGACATGGCGGGTGCAGCCATGTAT
GAGCTGGTGAGAGTGGGCCACAGCGAATTGGTTGGAGAGATTATTCGATTGGAGGGTGAC
ATGGCTACTATTCAGGTGTATGAAGAAACTTCTGGTGTGTCTGTTGGAGATCCTGTACTT
CGCACTGGTAAACCCCTCTCTGTAGAGCTTGGTCCTGGCATTATGGGAGCCATTTTTGAT
GGTATTCAAAGACCTTTGTCGGATATCAGCAGTCAGACCCAAAGCATCTACATCCCCAGA
GGAGTAAACGTGTCTGCTCTTAGCAGAGATATCAAATGGGACTTTACACCTTGCAAAAAC
CTACGGGTTGGTAGTCATATCACTGGCGGAGACATTTATGGAATTGTCAGTGAGAACTCG
CTTATCAAACACAAAATCATGTTACCCCCACGAAACAGAGGAACTGTAACTTACATTGCT
CCACCTGGGAATTATGATACCTCTGATGTTGTCTTGGAGCTTGAATTTGAAGGTGTAAAG
GAGAAGTTCACCATGGTGCAAGTATGGCCTGTACGTCAAGTTCGACCTGTCACTGAGAAG
CTGCCAGCCAATCATCCTCTGTTGACTGGCCAGAGAGTCCTTGATGCCCTTTTTCCGTGT
GTCCAGGGAGGAACTACTGCTATCCCTGGAGCCTTTGGCTGTGGAAAGACAGTGATATCA
CAGTCTCTATCCAAGTATTCTAACAGTGATGTAATCATCTATGTAGGATGTGGTGAAAGA
GGAAATGAGATGTCTGAAGTCCTCCGGGACTTCCCAGAGCTCACAATGGAGGTTGATGGT
AAGGTAGAGTCAATTATGAAGAGGACAGCTTTGGTAGCCAATACCTCCAATATGCCTGTT
GCTGCTAGAGAAGCCTCTATTTATACTGGAATCACACTGTCAGAGTACTTCCGTGACATG
GGCTATCATGTCAGTATGATGGCTGACTCTACCTCTAGATGGGCTGAGGCCCTTAGAGAA
ATCTCTGGTCGTTTAGCTGAAATGCCTGCAGATAGTGGATATCCAGCCTATCTTGGTGCC
CGTCTGGCCTCGTTTTATGAACGAGCAGGCAGGGTGAAATGTCTTGGAAATCCTGAAAGA
GAAGGGAGTGTCAGCATTGTAGGAGCAGTTTCTCCACCTGGTGGTGATTTTTCTGATCCA
GTTACATCTGCCACTCTTGGTATCGTTCAGGTGTTCTGGGGCTTAGATAAGAAACTAGCT
CAACGTAAGCATTTCCCCTCTGTCAATTGGCTCATCAGCTACAGCAAGTATATGCGTGCC
TTGGATGAATACTATGACAAACACTTCACAGAGTTCGTTCCTCTGAGGACGAAAGCTAAG
GAAATTCTGCAGGAAGAAGAAGACCTGGCAGAAATTGTACAGCTTGTGGGAAAGGCTTCT
TTGGCAGAAACAGATAAAATCACTCTGGAGGTAGCAAAACTTATCAAAGATGATTTCCTA
CAACAAAATGGATATACTCCTTATGACAGGTTCTGCCCATTCTACAAGACAGTAGGGATG
CTGTCCAACATGATTGCATTTTATGATATGGCTCGTAGAGCTGTTGAAACCACTGCCCAG
AGTGACAATAAAATCACATGGTCCATTATTCGTGAGCACATGGGAGACATCCTCTATAAA
CTTTCCTCCATGAAATTCAAGGATCCACTGAAAGATGGTGAGGCAAAGATCAAAAGCGAC
TATGCACAACTTCTTGAAGACATGCAGAATGCATTCCGTAGCCTTGAAGATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00006</identifier>
            <name>ATP-synt_ab</name>
          </pfam>
          <pfam>
            <identifier>PF00306</identifier>
            <name>ATP-synt_ab_C</name>
          </pfam>
          <pfam>
            <identifier>PF02874</identifier>
            <name>ATP-synt_ab_N</name>
          </pfam>
          <pfam>
            <identifier>PF16886</identifier>
            <name>ATP-synt_ab_Xtn</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>microvillus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proton-transporting two-sector ATPase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>proton-transporting V-type ATPase, V1 domain</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>proton-transporting ATPase activity, rotational mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ATP hydrolysis coupled proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ATP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phagosome maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transferrin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>